-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, CytoMed Therapeutics Limited Announces At The Market Offering Program For Up To $4.3M In Ordinary Shares Through R.F. Lafferty & Co Inc

Benzinga·08/19/2025 06:32:56
Listen to the news

The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversification and development initiatives and capital expenditures. We may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies.